Key Highlights
- Indegene acquires BioPharm Parent Holding, Inc. and its subsidiaries for up to USD 106 million
- Transaction structured as an all-cash deal with performance-based consideration
- BioPharm reported USD 38.13 million revenue in FY2024
- Acquisition enhances AI-powered AdTech and omnichannel marketing capabilities
- BioPharm serves 17 of the world’s top 25 biopharma companies
- Agreement signed on September 30, 2025 and completed on October 1, 2025
Bengaluru / Princeton / New Hope, October 1, 2025 – Indegene Limited has completed the acquisition of BioPharm Parent Holding, Inc. and its subsidiaries for up to USD 106 million, the company announced. The transaction was carried out through Indegene Ireland Limited and is structured as an all-cash deal with deferred, performance-based consideration.
BioPharm, headquartered in Pennsylvania, is a specialized healthcare marketing and communications agency that provides data-driven, omnichannel engagement solutions for pharmaceutical and biotech clients.
From a financial perspective, BioPharm reported unaudited revenues of USD 38.13 million in FY2024, compared to USD 35.97 million in 2023 and USD 40.89 million in 2022. The acquisition has been structured as an all-cash transaction valued at up to USD 106 million, subject to cash and net working capital adjustments, with provisions for deferred performance-based consideration.
Indegene said the acquisition will expand its AI-led AdTech and commercialization capabilities, combining analytics, automation and targeted engagement to deliver more measurable outcomes for life sciences customers. The deal positions Indegene to offer enhanced precision marketing, addressable media capabilities and improved media ROI for its clients.
Manish Gupta, Chairman and CEO of Indegene, said the acquisition reinforces the company’s role as a tech-native commercialization partner for the life sciences sector, adding that BioPharm’s expertise and client relationships complement Indegene’s data and AI capabilities. Steve Carickhoff, President of BioPharm, said joining Indegene will enable the firm to scale AI-powered marketing solutions and deliver greater value to clients worldwide.
The purchase agreement was signed on September 30, 2025, and the acquisition closed on October 1, 2025. Legal advisory for the transaction was provided by Seyfarth Shaw LLP.